The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Inactivating mutations of acetyltransferase genes in B-cell lymphoma
Open accessAbstract
B-cell non-Hodgkin’s lymphoma comprises biologically and clinically distinct diseases the pathogenesis of which is associated with genetic lesions affecting oncogenes and tumour-suppressor genes. We report here that the two most common types—follicular lymphoma and diffuse large B-cell lymphoma—harbour frequent structural alterations inactivating CREBBP and, more rarely, EP300, two highly related histone and non-histone acetyltransferases (HATs) that act as transcriptional co-activators in multiple signalling pathways. Overall, about 39% of diffuse large B-cell lymphoma and 41% of follicular lymphoma cases display genomic deletions and/or somatic mutations that remove or inactivate the HAT coding domain of these two genes. These lesions usually affect one allele, suggesting that reduction in HAT dosage is important for lymphomagenesis. We demonstrate specific defects in acetylation-mediated inactivation of the BCL6 oncoprotein and activation of the p53 tumour suppressor. These results identify CREBBP/EP300 mutations as a major pathogenetic mechanism shared by common forms of B-cell non-Hodgkin’s lymphoma, with direct implications for the use of drugs targeting acetylation/deacetylation mechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
WHO Classification: Tumours of the Haematopoietic and Lymphoid Tissues (2008)
(2015) · Postgraduate Haematology · doi:10.1002/9781118853771.ch51 · Cited by 3,290
The Transcriptional Coactivators p300 and CBP Are Histone Acetyltransferases
Ogryzko, V. V., Schiltz, R. L., Russanova, V., Howard, B. H., & Nakatani, Y. (1996) · Cell · doi:10.1016/s0092-8674(00)82001-2 · Cited by 2,952
The CBP co-activator is a histone acetyltransferase
Bannister, A. J., & Kouzarides, T. (1996) · Nature · doi:10.1038/384641a0 · Cited by 1,805
CBP/p300 in cell growth, transformation, and development
Goodman, R. H., & Smolik, S. (2000) · Genes & Development · doi:10.1101/gad.14.13.1553 · Cited by 1,778
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
Davis, R. E., Ngo, V. N., Lenz, G., Tolar, P., Young, R. M., Romesser, P. B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., et al. (2010) · Nature · doi:10.1038/nature08638 · Cited by 1,643
Morin, R. D., Johnson, N. A., Severson, T. M., Mungall, A. J., An, J., Goya, R., Paul, J. E., Boyle, M., Woolcock, B. W., Kuchenbauer, F., et al. (2010) · Nature Genetics · doi:10.1038/ng.518 · Cited by 1,521
Nuclear protein CBP is a coactivator for the transcription factor CREB
Kwok, R. P. S., Lundblad, J. R., Chrivia, J. C., Richards, J. P., Bächinger, H. P., Brennan, R. G., Roberts, S. G. E., Green, M. R., & Goodman, R. H. (1994) · Nature · doi:10.1038/370223a0 · Cited by 1,443
Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP
Petrif, F., Giles, R. H., Dauwerse, H. G., Saris, J. J., Hennekam, R. C. M., Masuno, M., Tommerup, N., van Ommen, G.-J. B., Goodman, R. H., Peters, D. J. M., et al. (1995) · Nature · doi:10.1038/376348a0 · Cited by 1,217
Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma
Compagno, M., Lim, W. K., Grunn, A., Nandula, S. V., Brahmachary, M., Shen, Q., Bertoni, F., Ponzoni, M., Scandurra, M., Califano, A., et al. (2009) · Nature · doi:10.1038/nature07968 · Cited by 1,038
Self-citationYao, T.-P., Oh, S. P., Fuchs, M., Zhou, N.-D., Ch'ng, L.-E., Newsome, D., Bronson, R. T., Li, E., Livingston, D. M., & Eckner, R. (1998) · Cell · doi:10.1016/s0092-8674(00)81165-4 · Cited by 1,014
Germinal centres: role in B-cell physiology and malignancy
Klein, U., & Dalla-Favera, R. (2008) · Nature Reviews Immunology · doi:10.1038/nri2217 · Cited by 901
Self-citationOncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma
Lenz, G., Davis, R. E., Ngo, V. N., Lam, L., George, T. C., Wright, G. W., Dave, S. S., Zhao, H., Xu, W., Rosenwald, A., et al. (2008) · Science · doi:10.1126/science.1153629 · Cited by 867
Acetylation Is Indispensable for p53 Activation
Tang, Y., Zhao, W., Chen, Y., Zhao, Y., & Gu, W. (2008) · Cell · doi:10.1016/j.cell.2008.03.025 · Cited by 838
Borrow, J., Stanton, V. P., Andresen, J. M., Becher, R., Behm, F. G., Chaganti, R. S. K., Civin, C. I., Disteche, C., Dubé, I., Frischauf, A. M., et al. (1996) · Nature Genetics · doi:10.1038/ng0996-33 · Cited by 771
Tip60-Dependent Acetylation of p53 Modulates the Decision between Cell-Cycle Arrest and Apoptosis
Tang, Y., Luo, J., Zhang, W., & Gu, W. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.11.021 · Cited by 727
Binding and modulation of p53 by p300/CBP coactivators
Lill, N. L., Grossman, S. R., Ginsberg, D., DeCaprio, J., & Livingston, D. M. (1997) · Nature · doi:10.1038/42981 · Cited by 693
The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells
Phan, R. T., & Dalla-Favera, R. (2004) · Nature · doi:10.1038/nature03147 · Cited by 679
Self-citationRecruitment of p300/CBP in p53-Dependent Signal Pathways
Avantaggiati, M. L., Ogryzko, V., Gardner, K., Giordano, A., Levine, A. S., & Kelly, K. (1997) · Cell · doi:10.1016/s0092-8674(00)80304-9 · Cited by 669
Iyer, N. G., Özdag, H., & Caldas, C. (2004) · Oncogene · doi:10.1038/sj.onc.1207118 · Cited by 638
CREBBP mutations in relapsed acute lymphoblastic leukaemia
Mullighan, C. G., Zhang, J., Kasper, L. H., Lerach, S., Payne-Turner, D., Phillips, L. A., Heatley, S. L., Holmfeldt, L., Collins-Underwood, J. R., Ma, J., et al. (2011) · Nature · doi:10.1038/nature09727 · Cited by 637
Self-citationSynergistic activation of transcription by CBP and p53
Gu, W., Shi, X.-L., & Roeder, R. G. (1997) · Nature · doi:10.1038/42972 · Cited by 596
Mutations truncating the EP300 acetylase in human cancers
Gayther, S. A., Batley, S. J., Linger, L., Bannister, A., Thorpe, K., Chin, S.-F., Daigo, Y., Russell, P., Wilson, A., Sowter, H. M., et al. (2000) · Nature Genetics · doi:10.1038/73536 · Cited by 587
Lenz, G., & Staudt, L. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0807082 · Cited by 528
CBP and p300: HATs for different occasions
Kalkhoven, E. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.03.045 · Cited by 496
BCoR, a novel corepressor involved in BCL-6 repression
Huynh, K. D., Fischle, W., Verdin, E., & Bardwell, V. J. (2000) · Genes & Development · doi:10.1101/gad.14.14.1810 · Cited by 477
Polyubiquitination of p53 by a Ubiquitin Ligase Activity of p300
Grossman, S. R., Deato, M. E., Brignone, C., Chan, H. M., Kung, A. L., Tagami, H., Nakatani, Y., & Livingston, D. M. (2003) · Science · doi:10.1126/science.1080386 · Cited by 459
The structural basis of protein acetylation by the p300/CBP transcriptional coactivator
Liu, X., Wang, L., Zhao, K., Thompson, P. R., Hwang, Y., Marmorstein, R., & Cole, P. A. (2008) · Nature · doi:10.1038/nature06546 · Cited by 448
Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP
Kung, A. L., Rebel, V. I., Bronson, R. T., Ch'ng, L.-E., Sieff, C. A., Livingston, D. M., & Yao, T.-P. (2000) · Genes & Development · doi:10.1101/gad.14.3.272 · Cited by 440
Acetylation inactivates the transcriptional repressor BCL6
Bereshchenko, O. R., Gu, W., & Dalla-Favera, R. (2002) · Nature Genetics · doi:10.1038/ng1018 · Cited by 394
Self-citationBlobel, G. A., Nakajima, T., Eckner, R., Montminy, M., & Orkin, S. H. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.5.2061 · Cited by 355
Phan, R. T., Saito, M., Basso, K., Niu, H., & Dalla-Favera, R. (2005) · Nature Immunology · doi:10.1038/ni1245 · Cited by 343
Self-citationSobulo, O. M., Borrow, J., Tomek, R., Reshmi, S., Harden, A., Schlegelberger, B., Housman, D., Doggett, N. A., Rowley, J. D., & Zeleznik-Le, N. J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.16.8732 · Cited by 319
Bedford, D. C., Kasper, L. H., Fukuyama, T., & Brindle, P. K. (2010) · Epigenetics · doi:10.4161/epi.5.1.10449 · Cited by 292
Self-citationTumors in Rubinstein‐Taybi syndrome
Miller, R. W., & Rubinstein, J. H. (1995) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320560125 · Cited by 283
Mandelbaum, J., Bhagat, G., Tang, H., Mo, T., Brahmachary, M., Shen, Q., Chadburn, A., Rajewsky, K., Tarakhovsky, A., Pasqualucci, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.030 · Cited by 282
Self-citationRegulating histone acetyltransferases and deacetylases
Legube, G., & Trouche, D. (2003) · EMBO reports · doi:10.1038/sj.embor.embor941 · Cited by 260
Rubinstein–Taybi syndrome: clinical and molecular overview
Roelfsema, J. H., & Peters, D. J. M. (2007) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399407000415 · Cited by 217
Rowley, J. D., Reshmi, S. C., Sobulo, O. M., Musvee, T., Anastasi, J., Raimondi, S. C., Schneider, N. R., Barredo, J. C., Cantú, E. S., Schlegelberger, B., et al. (1997) · PubMed · doi:10.1182/blood.v90.2.535 · Cited by 214
Oike, Y., Takakura, N., Hata, A., Kaname, T., Akizuki, M., Yamaguchi, Y., Yasue, H., Araki, K., Yamamura, K.-I., & Suda, T. (1999) · Blood · doi:10.1182/blood.v93.9.2771 · Cited by 184
CBP and p300 are cytoplasmic E4 polyubiquitin ligases for p53
Shi, D., Pop, M. S., Kulikov, R., Love, I. M., Kung, A. L., & Grossman, S. R. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904305106 · Cited by 161
HDAC inhibitor-based therapies and haematological malignancy
Stimson, L., Wood, V. H. J., Khan, O. A., Fotheringham, S. A., & Thangue, N. B. L. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn792 · Cited by 148
CBP/p300 double null cells reveal effect of coactivator level and diversity on CREB transactivation
Kasper, L. H., Lerach, S., Wang, J., Wu, S., Jeevan, T., & Brindle, P. K. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.235 · Cited by 115
Self-citationBordoli, L., Hüsser, S., Lüthi, U., Netsch, M., Osmani, H., & Eckner, R. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.21.4462 · Cited by 110
Preparation of a Low Molecular Weight Polyethylenimine for Efficient Cell Transfection
Bieber, T., & Elsässer, H. (2001) · BioTechniques · doi:10.2144/01301st03 · Cited by 80
Xu, W., Fukuyama, T., Ney, P. A., Wang, D., Rehg, J. E., Boyd, K. L., van Deursen, J. M. A., & Brindle, P. K. (2006) · Blood · doi:10.1182/blood-2005-08-3263 · Cited by 65
Self-citationShigeno, K., Yoshida, H., Pan, L., Luo, J. M., Fujisawa, S., Naito, K., Nakamura, S., Shinjo, K., Takeshita, A., Ohno, R., et al. (2003) · Cancer Letters · doi:10.1016/s0304-3835(03)00442-7 · Cited by 41
CBP truncating mutations in ovarian cancer
Ward, R. C., Johnson, M., Shridhar, V., van Deursen, J., & Couch, F. J. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2004.025080 · Cited by 34
A non-isotopic in vitro assay for histone acetylation
Kuninger, D., Lundblad, J. R., Semirale, A. A., & Rotwein, P. S. (2007) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2007.07.498 · Cited by 30
Garbati, M. R., Alço, G., & Gilmore, T. D. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.10.018 · Cited by 25
Cancer Genomes — Continuing Progress
Downing, J. R. (2009) · New England Journal of Medicine · doi:10.1056/nejme0906090 · Cited by 6
Cited by
Cancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203
A decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer
Robertson, A. G., Kim, J., Al-Ahmadie, H., Bellmunt, J., Guo, G., Cherniack, A. D., Hinoue, T., Laird, P. W., Hoadley, K. A., Akbani, R., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.007 · Cited by 2,443
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
Morin, R. D., Mendez-Lago, M., Mungall, A. J., Goya, R., Mungall, K. L., Corbett, R. D., Johnson, N. A., Severson, T. M., Chiu, R., Field, M., et al. (2011) · Nature · doi:10.1038/nature10351 · Cited by 1,614
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
Peifer, M., Fernández-Cuesta, L., Sos, M. L., George, J., Seidel, D., Kasper, L. H., Plenker, D., Leenders, F., Sun, R., Zander, T., et al. (2012) · Nature Genetics · doi:10.1038/ng.2396 · Cited by 1,397
Self-citation
Metadata
- Authors
- Pasqualucci, L., Dominguez-Sola, D., Chiarenza, A., Fabbri, G., Grunn, A., Trifonov, V., Kasper, L. H., Lerach, S., Tang, H., Ma, J., Rossi, D., Chadburn, A., Murty, V. V., Mullighan, C. G., Gaidano, G., Rabadan, R., Brindle, P. K., & Dalla-Favera, R.
- Venue
- Nature
- Published
- 2011-03
- Volume
- 471
- Issue
- 7337
- Pages
- 189-195
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2044352858
- Cited by
- 949
- References
- 51
- FWCI
- 49.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.